Non nucleoside reverse transcriptase inhibitors

Details Non nucleoside reverse transcriptase inhibitors Non nucleoside reverse transcriptase inhibitors

2003-04-25

2008-12-09

McKane, Joseph (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Phosphorus containing other than solely as part of an...

C544S090000

Reexamination Certificate

active

07462608

ABSTRACT:
Phosphorus-substituted imidazole compounds with anti-HIV properties having use as therapeutics and for other industrial purposes are disclosed. The compositions inhibit reverse transcriptase activity and are useful therapeutically for the inhibition of such enzymes, as well as in assays for the detection of such enzymes.

REFERENCES:
patent: 5413996 (1995-05-01), Bodor
patent: 5670497 (1997-09-01), Bold et al.
patent: 5750343 (1998-05-01), Maag et al.
patent: 5750493 (1998-05-01), Schinazi et al.
patent: 5874577 (1999-02-01), Chen et al.
patent: 5914332 (1999-06-01), Chen et al.
patent: 6072053 (2000-06-01), Vince et al.
patent: 6312662 (2001-11-01), Robinson et al.
patent: 6767900 (2004-07-01), Ubasawa et al.
patent: 2001/0031773 (2001-10-01), Camden
patent: 2003/0109498 (2003-06-01), Yuasa et al.
patent: 0 267 050 (1988-05-01), None
patent: 0 441 192 (1991-01-01), None
patent: 0 465 297 (1992-01-01), None
patent: 0 531 597 (1993-03-01), None
patent: 0 632 048 (1995-01-01), None
patent: 0 786 455 (1997-07-01), None
patent: 0 852 233 (1998-07-01), None
patent: 0 919 562 (1999-06-01), None
patent: 1 295 879 (2003-03-01), None
patent: WO 88/06158 (1988-08-01), None
patent: WO 91/19721 (1991-12-01), None
patent: WO 92/00988 (1992-01-01), None
patent: WO 92/18520 (1992-10-01), None
patent: WO 93/12123 (1993-06-01), None
patent: WO 93/24510 (1993-12-01), None
patent: WO 96/14314 (1996-05-01), None
patent: WO 96/40156 (1996-12-01), None
patent: WO 98/04569 (1998-02-01), None
patent: WO 98/11906 (1998-03-01), None
patent: WO 99/62921 (1999-12-01), None
patent: WO 00/04033 (2000-01-01), None
patent: WO 01/13957 (2001-03-01), None
patent: WO 01/17982 (2001-03-01), None
patent: WO 01/19320 (2001-03-01), None
patent: WO 01/46204 (2001-06-01), None
patent: WO 01/64693 (2001-09-01), None
patent: WO 01/96329 (2001-12-01), None
patent: WO 02/03997 (2002-01-01), None
patent: WO 02/06292 (2002-01-01), None
patent: WO 02/08241 (2002-01-01), None
patent: WO 02/14344 (2002-02-01), None
patent: WO 02/057425 (2002-07-01), None
patent: WO 02/100415 (2002-12-01), None
patent: WO 03/028737 (2003-04-01), None
patent: WO 03/050129 (2003-06-01), None
patent: WO 03/059255 (2003-07-01), None
patent: WO 03/064383 (2003-08-01), None
patent: WO 03/066005 (2003-08-01), None
patent: WO 03/080078 (2003-10-01), None
patent: WO 03/090690 (2003-11-01), None
patent: WO 2004/096234 (2004-11-01), None
patent: WO 2005/011709 (2005-02-01), None
U.S. Appl. No. 10/832,915, commonly owned.
U.S. Appl. No. 11/106,363, commonly owned.
U.S. Appl. No. 11/258,621, commonly owned.
Menendez-Aria, Luis. “Targeting HIV: an antiretroviral therapy and development of drug resistance,” Trends in Pharm. Sciences, vol. 23 (8), pp. 381-388.
Abdel-Meguid, Sherin S. et al., Inhibition of Human Immunodeficiency Virus-1 Protease by a C2-Symmetric Phosphinate. Synthesis and Crystallographic Analysis,Biochemistry, 1993, 1543-1572, vol. 32, No. 31.
Allen, Lee F. et al., CI-1040 (PDI84352), a Targeted Signal Transduction Inhibitor of MEK (MAPKK),Seminars in Oncology, Oct. 2003, pp. 105-106, vol. 30, No. 5, Elsevier Inc.
Bantia, Shanta et al., Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)—a novel potent and orally active immunosuppressive agent,International Immunopharmacology, 2001, pp. 1199-1210, Elsevier Science B.V.
Beauchamp, Lilia M., et al., Guanine, Pyrazolo[3,4-d]pyrimidine, and Triazolo[4,5-d]pyrimidine(8-Azaguanine) Phosphonate Acyclic Derivatives as Inhibitors of Purine Nucleoside Phosphorylase,Journal of Medicinal Chemistry, 1996, pp. 949-956, American Chemical Society.
Bohandi D. W. et al., A-420983: a potent, orally active inhibitor of Ick with efficacy in a model of transplant rejection,Bioorganic & Medicinal Chemistry Letters, 2004, vol. 14.
Bzowska, Agnieszka et al., Purine nucleoside phosphorylases: properties, functions, and clinical aspects,Pharmacology&Therapeutics, 2000, pp. 349-425, vol. 88, Elsevier Science Inc.
Chapman, H. et al., Practical Synthesis, Separation, and Stereochemical Assignment of the PMPA Pro-Drug GS-7340, Nucleosides, Nucleotides & Nucleic Acids, 2001, pp. 621-628, vol. 20, Nos. 4-7, Marcel Dekker, Inc.
Clark, Jeremy L. et al., Mycophenolic Acid Analogues as Potential Agents Against West Nile Virus Infection.
Conklyn, Maryrose et al., The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing,Journal of Leukocyte Biology, Dec. 2004, pp. 1-8, vol. 76, The Society for Leukocyte Biology.
De Clereq, E., Highlights in the Development of New Antiviral Agents,Mini Reviews in Medicinal Chemistry, 2002, 163-175, vol. 2, No. 2., Bentham Science Publishers, Ltd.
De Clercq, Erik, New Developments in Anti-HIV Chemotherapy,Current Medicinal Chemistry, 2001, 1543-1572, vol. 8, No. 13, Bentham Science Publishers Ltd.
Dvorakova, Hana et al., Synthesis of 2′-Aminomethyl Derivatives of N-(2-(Phosphonomethoxyl)ethyl) Nucleotide Analogues as Potential Antiviral Agents,J. Med. Chem., 1996, 3263-3268. vol. 38, No. 17.
Evans, Gary B., Exploring Structure—Activity Relationships of Transition State Analogues of Human Purine Nucleoside Phosphorylase,J. Med. Chem., 2003, 3412-3423, vol. 46, No. 15, American Chemical Society.
Gumina, Giuseppe et al., Advances in antiviral agents for hepatitis B virus,Antiviral Chemistry&Chemotherapy, 2001, 93-112, vol. 12, Suppl. 1, International Medical Press.
Gobec, S. et al., Phosphonate inhibitors of antiget 85C, a crucial enzyme involved in the biosynthesis of the mycobacterium tuberculosis cell wall,Bioorganic and Medicinal Chemistry Letters, 2004, vol. 14.
Hegedus, Louis S. et al., Synthesis of 4′-Methyl and 4′-cyano Carbocyclic 2′,3′-Didehydro Nucleoside Analogues via 1,4-Addition to Substituted Cyclopentenones,J. Org. Chem., 2004, 8492-8495, vol. 69, No. 24, American Chemical Society.
Herczegh P., et al., Osteoadsorptive bisphosphonate derivatives of fluoroquinolone antibacterials,J. Med. Chem., 2002, vol. 45.
Hirabayashi, Hideki et al., Bone-Specific Drug Delivery Systems,Clinical Pharacokinetics, 2003, 1319-1330, vol. 42, No. 15.
Holy A. et al., Synthesis,Cllect. Czech. Chem. Commun., 1989, vol. 54, pp. 2190-2210.
Jain, Jugnu et al., Characterization of Pharmacological Efficacy of VX-148, a New, Potent Immunosuppressive Inosine 5′-Monophosphate Dehydrogenase Inhibitor,Journal of Pharmacology and Experimental Therapeutics, 2002, 1272-1277, vol. 302, No. 3, The American Society for Pharmacology and Experimental Therapeutics.
Karpenko, Inna L. et al., Synthesis and Antitherpetic Activity of Acyclovir Phosphonates,Nucleosides, Nucleotides&Nucleic Acids, 2003, 319-328, vol. 22, No. 3, Marcel Dekker, Inc.
Kato, Keisuke et al., Stereoselective synthesis of 4′ -.alpha.-alkyclcarbovir derivatives based on an asymmetric synthesis or chemo-enzymatic procedure,Chemical&Pharmaceutical Bulletin, 1999, 1256-1264, vol. 49, No. 9, Pharmaceutical Society of Japan.
Kato, Keisuke et al., Enantio- and diastereoselective syntheis of 4′-α-substituted carbocyclic nucleosides, Tetrahedron:Asymmetry, 1998, 911-914, vol. 9, Elsevier Science Ltd.
Kilpatrick, J. Michael, Intravenous and oral pharmacokinetic study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor, In vivo effects on blood 2′-deoxyguanosine in primates,International Immunopharmacology, 2003, 541-548, vol. 3, Elsevier Science B.V.
Kim, Choung Un et al., Regiospecific and Highly Stereoselective Electrophilic Addition to Furanoid Glycals: Synthesis of Phosphonate Nucleotide Analogues with Potent Activity against HIV, J. Org. Chem., 1991, 2642-2647, vol. 56, No. 8, American Chemical Society.
Kinsky, Stephen C. et al., Inhibition of cell proliferation by putative metabolites and non-degradable analogs of methotrexate-.gama.-dimyristoylphosphatidylethanolamine,Biochimica et Biphysica Acta, 19878, 211-218, vol. 917, No. 2., Elsevier Science Publishers B. V.
Kinsky, Stephen C. et al., Effect of liposomes sentitized wi

Affiliated with

Also associated with

Rating

Non nucleoside reverse transcriptase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Non nucleoside reverse transcriptase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non nucleoside reverse transcriptase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4020470